<DOC>
	<DOC>NCT00902486</DOC>
	<brief_summary>This will be a randomized, double blind, placebo controlled, dose ranging, parallel group study. Subjects with active rheumatoid arthritis (RA) who have had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics will be enrolled. Screening evaluations will be performed within approximately 28 days of randomization. The duration of the study is 6 months with the primary endpoint assessed at 3 months. Eligible subjects will be randomly assigned to one of three doses (4, 7 or 10 mg QD) of INCB028050 or placebo.</brief_summary>
	<brief_title>INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Must have rheumatoid arthritis which has been inadequately controlled with at least one DMARD For subjects receiving antimalarials, they must be treated with antimalarials for at least 6 months and receiving a stable daily dose For subjects receiving sulfasalazine, they must be treated with SSZ for at least 6 months and receiving a stable daily dose of no more than 3 grams per day For subjects on methotrexate, they must be treated with methotrexate for at least 6 months, and receiving a stable weekly dose of methotrexate between 10 and 25 mg For subjects on leflunomide, they must be treated with leflunomide for at least 6 months, and receiving a stable dose of leflunomide between 10 to 20 mg For subjects receiving corticosteroids, they must be on a dose not to exceed 10 mg of prednisone daily Active rheumatoid arthritis at the time of screening defined by the following: 6 or more joints tender or painful on motion and 4 or more swollen joints and at least one of the following two: ESR greater than or equal to 28 mm/hr or CRP greater than or equal to 10 mg/liter.. Have evidence of lack of risk for tuberculosis Current or recent viral, bacterial, fungal, parasitic or mycobacterial infection requiring systemic therapy History of infected joint prosthesis Subjects who have a current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease Subjects who have received treatment with the following drugs or drug classes within the specified timeframe: prior treatment with rituximab within 12 months, prior treatment with an oral JAK inhibitor, DMARDs or other antirheumatic therapies not specified and allowed according to protocol, treatment with any investigational medication within 12 weeks or 5 halflives (whichever is longer), and treatment with a biologic agent within 12 weeks prior to the first dose of study medication. Subjects with a past history of neutropenia, thrombocytopenia or anemia requiring transfusion other than at the time of trauma or surgery, and subjects that meet protocol specified laboratory measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>